Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01014598 · ClinicalTrials.gov registry record · Phase 1
Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01014598 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 11 participants.
The verdict
NCT01014598, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of cisplatin in treating patients with stage IIIB-IV non-small cell lung cancer or tumors that have spread from where they started to the lung (metastasis). Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cisplatin directly into the arteries around the tumor may kill more tumor cells and cause less damage to normal tissue.
Interventions
- DRUG Cisplatin
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-12-04 |
| Est. Completion | 2017-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01014598
The ClinicalTrials.gov registry entry for NCT01014598 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin is the first listed.
NCT01014598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01014598 about?
NCT01014598 is a clinical study titled "Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis". This phase I trial studies the side effects and best dose of cisplatin in treating patients with stage IIIB-IV non-small cell lung cancer or tumors that have spread from where they started to the lung (metastasis). Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the gro...
What is the current status of trial NCT01014598?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2007-12-04. Estimated completion is 2017-05-01.
What interventions are being tested in trial NCT01014598?
The interventions under investigation include: Cisplatin (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01014598?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.